Results 121 to 130 of about 6,399,825 (302)
Widespread peritoneal dissemination is common in patients with gynecologic or gastrointestinal cancers. Accumulating evidence of a central role for regional immunity in cancer control indicates that intraperitoneal immunotherapy may have treatment ...
Ben Marwedel +9 more
doaj +1 more source
Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed. [PDF]
Fang L +7 more
europepmc +1 more source
POSTN‐CCL3 signaling forms a feed‐forward circuit between cardiomyocytes and cardiac myofibroblasts in arrhythmogenic cardiomyopathy. POSTN activates JNK/RIP3‐dependent necroptotic signaling and JNK/ETS2‐induced CCL3 expression in cardiomyocytes. In turn, CCL3‐CCR5 signaling in cardiac myofibroblasts activates NF‐κB/p65 and promotes POSTN expression ...
Tiantian Wu +12 more
wiley +1 more source
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. [PDF]
Frank MJ +23 more
europepmc +1 more source
This work presents a clinically deployable simultaneous PET/MRI workflow which integrates hyperpolarized 13C imaging of metabolism and extracellular pH with [18F]FMISO PET to characterize hypoxia, acidosis, and metabolic reprogramming in feline sarcoma.
Martin Grashei +17 more
wiley +1 more source
Background/Objectives: Fully personalized peptide vaccines targeting tumor-specific mutations are a promising treatment option for patients in an adjuvant but also advanced/metastatic disease situation in addition to non-personalized standard therapies ...
Armin Rabsteyn +13 more
doaj +1 more source
Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial. [PDF]
Nistor GI, Dillman RO.
europepmc +1 more source
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen +10 more
wiley +1 more source
Here, a PDL1 inhibitor is employed as a fifth component to modify lipid nanoparticles (LNPs). PDL1 inhibitor‐loaded LNPs show enhanced lymph node targeting, resulting in greater lymph node expansion, immune cell infiltration, and improved mRNA vaccine efficacy. This fifth component LNP could be a novel platform for mRNA vaccines.
Minki Ha +5 more
wiley +1 more source
[[abstract]]This study describes the feasibility and adjuvant mechanism of a degradable emulsion for tuning adaptive immune responses to a vaccine antigen.
Huang, CH;Huang, CY;Cheng, CP;Dai, SH;Chen, HW;Leng, CH;Chong, P;Liu, SJ;Huang, MH
core +1 more source

